PMID- 32655564
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20211204
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - The Superior Ability of Human BDCA3(+) (CD141(+)) Dendritic Cells (DCs) to 
      Cross-Present Antigens Derived From Necrotic Lung Cancer Cells.
PG  - 1267
LID - 10.3389/fimmu.2020.01267 [doi]
LID - 1267
AB  - Dendritic cells (DCs) play a key role in initiating and regulating the immune 
      responses to pathogens, self-antigens, and cancers. Human blood DCs comprise a 
      family of different subsets: plasmacytoid DCs (pDCs) and CD16(+), CD1c/BDCA1(+), 
      and BDCA3(+) (CD141(+)) myeloid DCs and possess different phenotypes and 
      functional characteristics. Lung cancer is the most common cancer, with the 
      highest morbidity and mortality in the world. However, which DC subset plays a 
      leading role in the lung cancer immune responses is unclear. We reanalyzed C-type 
      lectin domain family 9 member A (CLEC9A) and CD141 (THBD) gene expression 
      profiles from the Cancer Genome Atlas (TCGA) database and performed the 
      Kaplan-Meier survival analysis of overall survival for several cancers according 
      to their expression levels. Next, we investigated the capacities of five human 
      blood DC subsets to stimulate T cell proliferation and capture, process and 
      (cross-) present tumor antigen. Human BDCA3(+) (CD141(+)) DCs have a superior 
      capacity to stimulate allogeneic CD4(+)T cells proliferation and induce superior 
      Th1 response compared with other DC subsets. Interestingly, toll-like receptor 
      (TLR) agonists have little effect on DCs to induce the proliferation of naive 
      CD4(+) T cells, but contribute to their differentiation. Importantly, BDCA3(+) 
      (CD141(+)) DCs possess the most potent ability to cross-present human tumor 
      antigen after their uptake of necrotic lung cancer cells despite their lower 
      antigen uptake. These findings suggest that human BDCA3(+) (CD141(+)) DCs are 
      critical mediators of cytotoxic T lymphocyte responses against EGFR-positive lung 
      cancer. Therefore, our findings may provide theoretical basis for the development 
      of DC-based antitumor vaccines.
CI  - Copyright (c) 2020 Gu, Zhang, Ma, Liu, Li, Hu, Yang, Liang, Zeng, Wang and Liu.
FAU - Gu, Fei-Fei
AU  - Gu FF
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Zhang, Kai
AU  - Zhang K
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Ma, Li-Li
AU  - Ma LL
AD  - Department of Oncology, Wuhan Brain Hospital, Wuhan, China.
FAU - Liu, Yang-Yang
AU  - Liu YY
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Li, Chang
AU  - Li C
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Hu, Yue
AU  - Hu Y
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Yang, Qi-Fan
AU  - Yang QF
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Liang, Jin-Yan
AU  - Liang JY
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Zeng, Yu-Lan
AU  - Zeng YL
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Analysis and Testing Center, Institute of Hydrobiology, Chinese Academy of 
      Sciences, Wuhan, China.
FAU - Liu, Li
AU  - Liu L
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200619
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Antigens, Surface)
RN  - 0 (THBD protein, human)
RN  - 0 (Thrombomodulin)
SB  - IM
MH  - Antigens, Neoplasm/*immunology
MH  - Antigens, Surface/immunology
MH  - Cells, Cultured
MH  - Cross-Priming/*immunology
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Lung Neoplasms/*immunology
MH  - Necrosis/immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Thrombomodulin
PMC - PMC7325999
OTO - NOTNLM
OT  - EGFR
OT  - TLR
OT  - antitumor vaccine
OT  - cytotoxic T lymphocyte
OT  - dendritic cell
OT  - lung cancer
EDAT- 2020/07/14 06:00
MHDA- 2021/04/07 06:00
PMCR- 2020/01/01
CRDT- 2020/07/14 06:00
PHST- 2019/11/04 00:00 [received]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2020.01267 [doi]
PST - epublish
SO  - Front Immunol. 2020 Jun 19;11:1267. doi: 10.3389/fimmu.2020.01267. eCollection 
      2020.